Literature DB >> 22348171

Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging.

Esin Ozturk-Isik1, Andrea Pirzkall, Kathleen R Lamborn, Soonmee Cha, Susan M Chang, Sarah J Nelson.   

Abstract

The spatial heterogeneity in magnetic resonance (MR) metabolic and diffusion parameters and their relationship were studied for patients with treatment-naive grade 3 gliomas. MR data were evaluated from 51 patients with newly diagnosed grade 3 gliomas. Anatomic, diffusion, and metabolic imaging data were considered. Variations in metabolite levels, apparent diffusion coefficient (ADC), and fractional anisotropy (FA) were evaluated in regions of gadolinium enhancement and T2 hyperintensity as well as regions with abnormal metabolic signatures. Contrast enhancement was present in only 21 of the 51 patients. When present, the enhancing component of the lesion had higher choline-to-N-acetylaspartate index (CNI), higher choline, lower N-acetylaspartate, similar creatine, similar ADC and FA, and higher lactate/lipid than the nonenhancing lesion. Regions with CNI ≥ 4 had higher choline, lower N-acetylaspartate, higher lactate/lipid, higher ADC, and lower FA than normal-appearing white matter and regions with intermediate CNI values. For lesions that exhibited gadolinium enhancement, the metabolite levels and diffusion parameters in the region of enhancement were consistent with it corresponding to the most abnormal portion of the tumor. For nonenhancing lesions, areas with CNI ≥ 4 were the most abnormal in metabolic and diffusion parameters. This suggests that the region with the highest CNI might provide a good target for biopsies for nonenhancing lesions to obtain a representative histologic diagnosis of its degree of malignancy. Metabolic and diffusion parameter levels may be of interest not only for directing tissue sampling but also for defining the targets for focal therapy and assessing response to therapy.

Entities:  

Year:  2012        PMID: 22348171      PMCID: PMC3281410          DOI: 10.1593/tlo.11208

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  49 in total

Review 1.  Imaging of brain tumors after therapy.

Authors:  S J Nelson
Journal:  Neuroimaging Clin N Am       Date:  1999-11       Impact factor: 2.264

2.  A simplified method to measure the diffusion tensor from seven MR images.

Authors:  P J Basser; C Pierpaoli
Journal:  Magn Reson Med       Date:  1998-06       Impact factor: 4.668

3.  Improved solvent suppression and increased spatial excitation bandwidths for three-dimensional PRESS CSI using phase-compensating spectral/spatial spin-echo pulses.

Authors:  J Star-Lack; D B Vigneron; J Pauly; J Kurhanewicz; S J Nelson
Journal:  J Magn Reson Imaging       Date:  1997 Jul-Aug       Impact factor: 4.813

4.  Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery.

Authors:  E E Graves; S J Nelson; D B Vigneron; L Verhey; M McDermott; D Larson; S Chang; M D Prados; W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

5.  Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas.

Authors:  Isabelle Catalaa; Roland Henry; William P Dillon; Edward E Graves; Tracy R McKnight; Ying Lu; Daniel B Vigneron; Sarah J Nelson
Journal:  NMR Biomed       Date:  2006-06       Impact factor: 4.044

6.  Disarrangement of fiber tracts and decline of neuronal density correlate in glioma patients--a combined diffusion tensor imaging and 1H-MR spectroscopy study.

Authors:  E Goebell; J Fiehler; X-Q Ding; S Paustenbach; S Nietz; O Heese; T Kucinski; C Hagel; M Westphal; H Zeumer
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

7.  Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors.

Authors:  A Lin; S Bluml; A N Mamelak
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

Review 8.  Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI.

Authors:  S J Nelson; D B Vigneron; W P Dillon
Journal:  NMR Biomed       Date:  1999-05       Impact factor: 4.044

9.  Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas.

Authors:  Andreas Stadlbauer; Ewald Moser; Stephan Gruber; Rolf Buslei; Christopher Nimsky; Rudolf Fahlbusch; Oliver Ganslandt
Journal:  Neuroimage       Date:  2004-10       Impact factor: 6.556

10.  Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

Authors:  Forrest W Crawford; Inas S Khayal; Colleen McGue; Suja Saraswathy; Andrea Pirzkall; Soonmee Cha; Kathleen R Lamborn; Susan M Chang; Mitchel S Berger; Sarah J Nelson
Journal:  J Neurooncol       Date:  2008-11-15       Impact factor: 4.130

View more
  2 in total

1.  Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes.

Authors:  N Andres Parra; Andrew A Maudsley; Rakesh K Gupta; Fazilat Ishkanian; Kris Huang; Gail R Walker; Kyle Padgett; Bhaswati Roy; Joseph Panoff; Arnold Markoe; Radka Stoyanova
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-24       Impact factor: 7.038

2.  A comparison of coil combination strategies in 3D multi-channel MRSI reconstruction for patients with brain tumors.

Authors:  Maryam Vareth; Janine Lupo; Peder Larson; Sarah Nelson
Journal:  NMR Biomed       Date:  2018-08-31       Impact factor: 4.044

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.